Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia

Trial Profile

Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Dihydroartemisinin/piperaquine (Primary)
  • Indications Malaria
  • Focus Therapeutic Use
  • Sponsors PATH
  • Most Recent Events

    • 20 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
    • 15 Dec 2016 Results published in the Journal of Infectious Diseases
    • 09 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top